ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Immunotech Biopharm Ltd. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 0% and Operating profit at 0.47% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -55.24
2
Flat results in Jun 25
- CASH AND EQV(HY) Lowest at HKD 23.06 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -31.66%, its profits have risen by 53.8%
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -31.66% returns in the last 1 year, the stock has also underperformed Hang Seng Hong Kong in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Immunotech Biopharm Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Immunotech Biopharm Ltd.
-31.66%
-0.09
68.22%
Hang Seng Hong Kong
8.25%
0.41
19.93%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0.47%
EBIT to Interest (avg)
-55.24
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-17.48
Sales to Capital Employed (avg)
0
Tax Ratio
0.30%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-17.38
EV to EBIT
-14.41
EV to EBITDA
-21.74
EV to Capital Employed
-22.13
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend9What is working for the Company
OPERATING CASH FLOW(Y)
Highest at HKD -278.36 MM
NET PROFIT(HY)
Higher at HKD -84.51 MM
ROCE(HY)
Highest at 0%
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
OPERATING PROFIT(Q)
Highest at HKD -62.63 MM
-1What is not working for the Company
CASH AND EQV(HY)
Lowest at HKD 23.06 MM
Here's what is working for Immunotech Biopharm Ltd.
Operating Cash Flow
Highest at HKD -278.36 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (HKD MM)
Net Profit
Higher at HKD -84.51 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (HKD MM)
Operating Profit
Highest at HKD -62.63 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (HKD MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Immunotech Biopharm Ltd.
Cash and Eqv
Lowest at HKD 23.06 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
